3349 — Cosmos Pharmaceutical Share Price
Last trade - 00:00- ¥572bn
- ¥564bn
- ¥828bn
- 75
- 30
- 48
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.35 | ||
| PEG Ratio (f) | 3.04 | ||
| EPS Growth (f) | 7.55% | ||
| Dividend Yield (f) | 0.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.55 | ||
| Price to Tang. Book | 2.56 | ||
| Price to Free Cashflow | 839.71 | ||
| Price to Sales | 0.61 | ||
| EV to EBITDA | 11.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.09% | ||
| Return on Equity | 11.63% | ||
| Operating Margin | 3.36% | ||
Financial Summary
| Year End 31st May | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 611,137 | 684,403 | 726,424 | 755,414 | 827,697 | 961,747 | 1,048,532 | 8.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +9.04 | +15.34 | +13.3 | -8.68 | +4.35 | +4.04 | +7.96 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
COSMOS Pharmaceutical Corporation is a company primarily engaged in the operation of drug stores. The Company offers medical goods, including general self-medication products, tonic drinks, oral care products, nursing care products, vitamin supplements, health food products, diet food and dispensing. Cosmetic products include cosmetic products for women and men, hair care products and bath agents. Miscellaneous goods include baby goods, detergents, insecticides, deodorizers, bath goods, toiletries, cookware, gardening goods, automobile goods and clothing products. General food products include processed food products, daily food products, seasonings, confectionery, non-alcoholic beverages and alcoholic beverages. It also provides tobacco and others.
Directors
- Masateru Uno CHM (73)
- Hideaki Yokoyama PRE (40)
- Masahiro Iwashita EXO (58)
- Motoi Takemori FID (56)
- Yukitaka Uno EXO (47)
- Futoshi Shibata OTH (49)
- Michiyoshi Kosaka DRC (60)
- Chiyoko Harada IND (47)
- Masao Ueda IND (70)
- Last Annual
- May 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- December 3rd, 1983
- Public Since
- November 11th, 2004
- No. of Shareholders
- 24,639
- No. of Employees
- 5,290
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 39,628,838
- Address
- 4F, S Kan, Daiichi Fukuoka Bldg., FUKUOKA-SHI, 812-0013
- Web
- https://www.cosmospc.co.jp/
- Phone
- +81 924330660
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 3349
Upcoming Events for 3349
Dividend For 3349.T - 60.0000 JPY
Full Year 2024 Cosmos Pharmaceutical Corp Earnings Release
Cosmos Pharmaceutical Corp Annual Shareholders Meeting
Q1 2025 Cosmos Pharmaceutical Corp Earnings Release
Similar to 3349
Aeon Co
Tokyo Stock Exchange
Ain Holdings
Tokyo Stock Exchange
Albis Co
Tokyo Stock Exchange
Aoki Super Co
Tokyo Stock Exchange
Arcs Co
Tokyo Stock Exchange
FAQ
As of Today at 19:06 UTC, shares in Cosmos Pharmaceutical are trading at ¥14,430. This share price information is delayed by 15 minutes.
Shares in Cosmos Pharmaceutical last closed at ¥14,430 and the price had moved by +13.98% over the past 365 days. In terms of relative price strength the Cosmos Pharmaceutical share price has underperformed the Nikkei 225 Index by -14.22% over the past year.
The overall consensus recommendation for Cosmos Pharmaceutical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Cosmos Pharmaceutical dividend yield is 0.81% based on the trailing twelve month period.
Last year, Cosmos Pharmaceutical paid a total dividend of ¥118, and it currently has a trailing dividend yield of 0.81%.Looking ahead, shares in Cosmos Pharmaceutical are due to go ex-dividend on 2024-05-30 and the next dividend pay date is 2024-08-01.
Cosmos Pharmaceutical are due to go ex-dividend on 2024-05-30 and the next dividend pay date is 2024-08-01. The historic dividend yield on Cosmos Pharmaceutical shares is currently 0.81%.
To buy shares in Cosmos Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥14,430, shares in Cosmos Pharmaceutical had a market capitalisation of ¥572bn.
Here are the trading details for Cosmos Pharmaceutical:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 3349
Based on an overall assessment of its quality, value and momentum Cosmos Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cosmos Pharmaceutical is ¥16,804. That is 16.45% above the last closing price of ¥14,430.
Analysts covering Cosmos Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of ¥631 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cosmos Pharmaceutical. Over the past six months, its share price has underperformed the Nikkei 225 Index by -17.65%.
As of the last closing price of ¥14,430, shares in Cosmos Pharmaceutical were trading -6.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cosmos Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 21.35. The shares last closed at ¥14,430.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cosmos Pharmaceutical's management team is headed by:
- Masateru Uno - CHM
- Hideaki Yokoyama - PRE
- Masahiro Iwashita - EXO
- Motoi Takemori - FID
- Yukitaka Uno - EXO
- Futoshi Shibata - OTH
- Michiyoshi Kosaka - DRC
- Chiyoko Harada - IND
- Masao Ueda - IND